• COVID-19 News: NIST Shares Synthetic Virus For Test Validation, Published Results of Retesting, More

    Aug 14 | Diagnostics World News | New COVID-19 risk model developed by Cleveland Clinic and published findings from a retesting study. Plus, symptom trackers deployed by colleges for Back to School and quantified synthetic virus fragments available from NIST. More
  • PacBio, Asuragen Collaborate on Carrier Screening Assays

    Aug 11 | Diagnostics World News | Pacific Biosciences and Asuragen have launched a clinical research collaboration aimed at developing molecular assays based on PacBio’s Single Molecule, Real-Time (SMRT) Sequencing technology. More
  • The Long Game On Telehealth

    Aug 11 | Diagnostics World News | As the pandemic has dragged on, medical practices everywhere have also started thinking seriously about how to better fit telehealth into their patient care workflow over the long term. More
  • FDA Approves First COVID-19 Serology Tests, Other News

    Aug 07 | Diagnostics World News | In a report in the Journal of Molecular Diagnostics, researchers describe a cheaper, rapid, and accurate pooling strategy for the RT-PCR-based detection of SARS-CoV-2 in clinical samples. Elsewhere, the U.S. Food and Drug Administration has authorized the first two COVID-19 serology tests that display an estimated quantity of antibodies present in the individual’s blood. This, plus more, is included in this week’s COVID-19 news and research in the diagnostics industry. More
  • Next Generation Dx Summit Goes Virtual Offering Even More Content, Opportunities

    Aug 05 | Diagnostics World NewsThe Next Generation Dx Summit is going virtual later this month, offering a rich content experience with even more opportunity to learn through on demand sessions, live panel discussions, and plenty of digital networking events including a robust exhibit hall. More
  • Follow the Money: Pan-Cancer Liquid Biopsy Investments, CBC from Finger-Stick Blood

    Aug 05 | Diagnostics World News | Big investments in liquid biopsy this month, with $257M for a pan-cancer test from Thrive Earlier Detection and another $72M for complete blood count analysis from finger-stick blood. COVID-19 gets diagnostics funding too, pushing toward six million daily tests. More
  • MUSC Stretching ICU Surge Capacity To Statewide Proportions

    Aug 04 | Diagnostics World News | The Medical University of South Carolina is trying to quickly stand up a telemedicine system to increase ICU surge capacity across the state during the ongoing COVID-19 outbreak. More
  • Ancestry Launches NGS Tests With Family History Component

    Aug 04 | Diagnostics World News | Ancestry has launched AncestryHealth powered by Next Generation Sequencing. It is an upgrade to AncestryDNA + Traits, adding genetic health risk reports, a family health history tool, and other resources. More
  • European Diagnostics Market In Flux During, After COVID-19

    Aug 03 | Diagnostics World News | In June, the Economist Intelligence Unit released an overview of the European in vitro diagnostics market pre- and post-COVID-19. More
  • New Testing Methods, Analysis of Sampling Techniques: COVID-19 Updates

    Jul 31 | Diagnostics World News | Diagnostic methods for SARS-CoV-2 are being refined with researchers studying sampling techniques, identifying early biomarkers of severe disease, and more. The diagnostics industry continues to rise to the need, releasing new tests and sharing resources to speed diagnosis and patient stratification. More
View more articles


Sino Biological

SARS-CoV-2 Detection Antigens and Antibodies

To support the studies on the development of rapid diagnostic tools, vaccines and therapeutic antibodies for COVID-19, Sino Biological has developed a comprehensive panel of research reagents for the Novel Coronavirus SARS-CoV-2, including Recombinant Antigens (N protein, S protein, S1 and S2 subunits of S protein, and RBD domain of S protein), Monoclonal Antibodies, and Antigen Detection Kits.

Click for more information


2020 Global Coronavirus Diagnostics Market

The report presents a detailed analysis of the Coronavirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Coronavirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: Hospitals, Commercial/Private Labs, Physician Offices and Public Health Labs.

Global Molecular Diagnostics Partnering 2014-2019: Deal trends, players, financials and forecasts

The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals. The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyze and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic deal making market.